AP
BMY.RT

Advisor Partners’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Advisor Partners’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-17,441
Closed -$37.1K – 756
2020
Q3 		$39K Sell
17,441
-1,895
-10% -$5.41K ﹤0.01% 698
2020
Q2 		$69K Sell
19,336
-3,243
-14% -$11.7K 0.01% 677
2020
Q1 		$85K Buy
+22,579
New +$74.4K 0.01% 597
2019
Q4 		– Hold
0
– – – 623

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BFS
Bard Financial Services Branford, Connecticut $911M AUM 19.14% 1-Year Est. Return
LGP
Leonard Green & Partners Los Angeles, California $2.77B AUM 3.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Advisor Partners's BMY.RT Position: Q4 2020 in Review

Advisor Partners sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 17,441 shares — an estimated $37.1K sold.

Advisor Partners first reported a position in BMY.RT in Q1 2020 and held it in 3 quarters. The position peaked at $85K in Q1 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

  • Advisor Partners reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
  • Advisor Partners sold 17,441 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $37.1K.
  • Advisor Partners first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 3 quarters.
  • Advisor Partners's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $85K in Q1 2020.
  • 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Advisor Partners's 13F filing for Q4 2020, filed 12 Feb 2021.